Stock comparison
Haemonetics
Stryker
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
SYK
Stryker
Market cap
$121.8B
Sector
Healthcare
Overall winner
Stryker SYK
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HAE | SYK | Winner |
|---|---|---|---|
| Warren Buffett | 70B | 65B | HAE |
| Benjamin Graham | 85A | 83A | HAE |
| Philip Fisher | 60C | 67C | SYK |
| Peter Lynch | 54C | 68B | SYK |
| Joel Greenblatt | 31F | 50D | SYK |
| Charlie Munger | 54D | 63D | SYK |
| Terry Smith | 55D | 62D | SYK |
Side-by-side metrics
| Metric | HAE | SYK |
|---|---|---|
| Market cap | $2.98B | $121.8B |
| P/E (TTM) | 24.8x | 35.2x |
| EV/EBIT | 14.1x | 26.4x |
| ROIC (TTM) | 8.37% | 9.79% |
| Gross margin | 55.74% | 63.67% |
| Net margin | 7.29% | 13.21% |
| Revenue CAGR 5y | 7.65% | 10.07% |
| EPS CAGR 5y | 24.62% | 12.55% |
| Debt / Equity | 1.5x | 0.6x |
| Dividend yield | 0.0% | 1.12% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HAE leads on
- EPS CAGR 5y24.62%vs 12.55%+49%
- EV/EBIT14.1xvs 26.4x+46%
- P/E (TTM)24.8xvs 35.2x+29%
SYK leads on
- Dividend yield1.12%vs 0.0%+100%
- Market cap$121.8Bvs $2.98B+98%
- Debt / Equity0.6xvs 1.5x+59%
- Net margin13.21%vs 7.29%+45%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.